BeOne Medicines (ONC) legal chief exercises options, sells 332 ADS

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

BeOne Medicines Ltd. SVP and General Counsel Lee Chan Henry exercised stock options and sold depositary shares in a planned transaction. On April 8, 2026, he exercised options for a total of 4,316 Ordinary Shares at exercise prices of $14.96, $16.41, and $12.23 per share.

These option exercises were represented through 332 American Depositary Shares (ADS), which were then sold at $311.59 per ADS under a pre-arranged Rule 10b5-1 trading plan. Each ADS represents 13 Ordinary Shares. After these transactions and related holdings, he directly holds 318,370 Ordinary Shares, indicating this was a routine liquidity event while maintaining a substantial equity stake.

Insider Trade Summary 10b5-1

Net Seller: 332 shares ($103,448)

Net Sell 8 txns

Insider Lee Chan Henry

Role SVP, General Counsel

Sold 332 shs ($103K)

Type	Security	Shares	Price	Value
Exercise	Share Option (Right to Buy)	1,313	$0.00	--
Exercise	Share Option (Right to Buy)	1,729	$0.00	--
Exercise	Share Option (Right to Buy)	1,274	$0.00	--
Exercise	American Depositary Shares	101	$194.47	$20K
Exercise	American Depositary Shares	133	$213.32	$28K
Exercise	American Depositary Shares	98	$159.03	$16K
Sale	American Depositary Shares	332	$311.59	$103K
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Share Option (Right to Buy) — 21,177 shares (Direct); American Depositary Shares — 101 shares (Direct); Ordinary Shares — 318,370 shares (Direct)

Footnotes (1)

Each American Depositary Share represents 13 Ordinary Shares. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2025. The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Key Figures

Options exercised: 4,316 Ordinary Shares ADS sold: 332 ADS Sale price per ADS: $311.59 +4 more

7 metrics

Options exercised 4,316 Ordinary Shares Total underlying shares from three option exercises on April 8, 2026

ADS sold 332 ADS Open-market or private sale corresponding to 4,316 Ordinary Shares

Sale price per ADS $311.59 Price for 332 American Depositary Shares sold on April 8, 2026

ADS share ratio 13 Ordinary Shares per ADS Each American Depositary Share represents 13 Ordinary Shares

Post-transaction holdings 318,370 Ordinary Shares Direct Ordinary Share holdings after reported transactions

Option exercise prices $14.96, $16.41, $12.23 Exercise prices for three option grants converted into Ordinary Shares

Rule 10b5-1 plan date May 14, 2025 Adoption date of trading plan governing the ADS sale

Key Terms

American Depositary Shares, Rule 10b5-1 trading plan, Share Option (Right to Buy, vest over a four-year period, +1 more

5 terms

American Depositary Shares financial

"The number of securities underlying each option and the exercise price therefore are represented in ordinary shares."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Rule 10b5-1 trading plan regulatory

"The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

vest over a four-year period financial

"These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments"

accelerated vesting financial

"Unvested securities are subject to accelerated vesting upon certain termination events."

Form 4 Insider Transactions: What Each Field Means →

04/10/2026 - 05:40 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lee Chan Henry

(Last)

(First)

(Middle)

C/O BEONE MEDICINES I GMBH

AESCHENGRABEN 27, 21ST FLOOR

(Street)

BASEL

4051

(City)

(State)

(Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares								318,370	D
American Depositary Shares⁽¹⁾	04/08/2026		M		101	A	$194.47	101	D
American Depositary Shares⁽¹⁾	04/08/2026		M		133	A	$213.32	234	D
American Depositary Shares⁽¹⁾	04/08/2026		M		98	A	$159.03	332	D
American Depositary Shares⁽¹⁾	04/08/2026		S⁽²⁾		332	D	$311.59	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Share Option (Right to Buy)	$14.96⁽³⁾	04/08/2026		M			1,313	⁽⁴⁾	08/04/2032	Ordinary Shares	1,313	$0	21,177	D
Share Option (Right to Buy)	$16.41⁽³⁾	04/08/2026		M			1,729	⁽⁵⁾	06/14/2033	Ordinary Shares	1,729	$0	84,955	D
Share Option (Right to Buy)	$12.23⁽³⁾	04/08/2026		M			1,274	⁽⁶⁾	06/04/2034	Ordinary Shares	1,274	$0	109,122	D

Explanation of Responses:

1. Each American Depositary Share represents 13 Ordinary Shares.

2. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2025.

3. The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.

4. These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

5. These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

6. These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Remarks:

	/s/ Qing Nian, as Attorney-in-Fact	04/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did BeOne Medicines (ONC) executive Lee Chan Henry do in this Form 4 filing?

Lee Chan Henry, SVP and General Counsel of BeOne Medicines, exercised stock options and sold American Depositary Shares. He converted options into 4,316 Ordinary Shares and then sold 332 ADS, representing those shares, in a planned transaction under a Rule 10b5-1 trading plan.

How many BeOne Medicines (ONC) shares did the executive sell and at what price?

He sold 332 American Depositary Shares at $311.59 per ADS. Each ADS represents 13 Ordinary Shares, so the sale corresponded to 4,316 Ordinary Shares. The transaction was reported as an open-market or private sale under SEC code S.

What stock options did the BeOne Medicines (ONC) executive exercise?

He exercised three tranches of Share Options for 1,313, 1,729, and 1,274 Ordinary Shares. The respective exercise prices were $14.96, $16.41, and $12.23 per share, with option expiration dates in 2032, 2033, and 2034 as disclosed in the filing.

Was the BeOne Medicines (ONC) insider sale made under a Rule 10b5-1 trading plan?

Yes. A footnote states the sale was effected under a Rule 10b5-1 trading plan adopted on May 14, 2025. Such pre-arranged plans are established in advance and are designed to make transactions more routine and less influenced by short-term information.

How many BeOne Medicines (ONC) shares does Lee Chan Henry hold after these transactions?

After the reported transactions, he directly holds 318,370 Ordinary Shares. The filing also shows no remaining derivative positions in the derivative summary, indicating the reported options tied to these transactions were fully exercised by the transaction date.

What is the relationship between BeOne Medicines’ American Depositary Shares and Ordinary Shares?

A footnote clarifies that each American Depositary Share represents 13 Ordinary Shares of BeOne Medicines. In this filing, 332 ADS correspond to 4,316 Ordinary Shares, providing the link between the option exercises and the ADS sale reported.